Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The diagnostics and life sciences equipment industry rarely stands still.</li><li>But recent developments around Agilent Technologies have drawn fresh attention from investors.</li><li>The company recently announced an agreement to acquire Biocare Medical for roughly $950 million in cash, a deal designed to deepen its presence in pathology and diagnostic testing.</li></ul>

The diagnostics and life sciences equipment industry rarely stands still.But recent developments around Agilent Technologies have drawn fresh attention from investors.The company recently announced an agreement to acquire Biocare Medical for roughly $950 million in cash, a deal designed to deepen its presence in pathology and diagnostic testing.

Did Agilent Just Buy Growth Or Create A Hidden Diagnostics SHIFT?

<ul><li>Agilent Technologies Inc. reported fiscal Q1 2026 revenue of about $1.8 billion, representing 4.4% core growth and 7% reported growth, largely in line with expectations despite severe U.S. winter weather delaying roughly $10 million in shipments.</li><li>Most of the delayed revenue was recovered shortly after quarter end, indicating a timing issue rather than weaker demand.</li><li>Operating margin was 24.6%, slightly lower year over year due to tariff headwinds and normalization of performance-based compensation.</li></ul>

Agilent Technologies Inc. reported fiscal Q1 2026 revenue of about $1.8 billion, representing 4.4% core growth and 7% reported growth, largely in line with expectations despite severe U.S. winter weather delaying roughly $10 million in shipments.Most of the delayed revenue was recovered shortly after quarter end, indicating a timing issue rather than weaker demand.Operating margin was 24.6%, slightly lower year over year due to tariff headwinds and normalization of performance-based compensation.

Agilent Technologies: Riding The GLP-1 Therapeutics Wave Across Global Pharmaceutical Laboratories!

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

<ul><li>Agilent Technologies, Inc. recently reported its fourth-quarter results for fiscal year 2025, showcasing robust performance across numerous dimensions.</li><li>The company's revenue for the quarter was $1.86 billion, representing growth of 7.2% on a core basis.</li><li>This marked Agilent's sixth consecutive quarter of core revenue growth acceleration, with the results surpassing the high end of their guidance range.</li></ul>

Agilent Technologies, Inc. recently reported its fourth-quarter results for fiscal year 2025, showcasing robust performance across numerous dimensions.The company's revenue for the quarter was $1.86 billion, representing growth of 7.2% on a core basis.This marked Agilent's sixth consecutive quarter of core revenue growth acceleration, with the results surpassing the high end of their guidance range.

Agilent Technologies: What the Next Instrument Cycle Looks Like—Inside the LC & LC/MS Modernization Tailwind!

Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Agilent is a well-positioned leader in the life sciences, diagnostics, and applied chemical markets, benefiting from a strong brand, diverse product portfolio, and significant recurring revenue streams from consumables and services.</li>
  <li>The company's strategic focus on high-growth areas like biopharmaceuticals, cancer diagnostics, and PFAS testing, coupled with strategic acquisitions, is expected to drive future growth despite near-term macroeconomic headwinds.</li>
  <li>A strong competitive moat, built on high customer switching costs, technological expertise, and a global presence, provides financial resilience and supports consistent margin expansion and shareholder returns.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Agilent is a well-positioned leader in the life sciences, diagnostics, and applied chemical markets, benefiting from a strong brand, diverse product portfolio, and significant recurring revenue streams from consumables and services.
  The company's strategic focus on high-growth areas like biopharmaceuticals, cancer diagnostics, and PFAS testing, coupled with strategic acquisitions, is expected to drive future growth despite near-term macroeconomic headwinds.
  A strong competitive moat, built on high customer switching costs, technological expertise, and a global presence, provides financial resilience and supports consistent margin expansion and shareholder returns.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Agilent Technologies  (A UN) - Sep 2025

United States

Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences, and chemical analysis industries. The Company offers electronic and bio-analytical measurement, semiconductor, and board testing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Agilent Technologies (A US)

Did Agilent Just Buy Growth Or Create A Hidden Diagnostics SHIFT?

The diagnostics and life sciences equipment industry rarely stands still. But recent developments around Agilent Technologies have drawn fresh...

Baptista Research

Agilent Technologies: Riding The GLP-1 Therapeutics Wave Across Global Pharmaceutical Laboratories!

Agilent Technologies Inc. reported fiscal Q1 2026 revenue of about $1.8 billion, representing 4.4% core growth and 7% reported growth, largely in...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Agilent Technologies: What the Next Instrument Cycle Looks Like—Inside the LC & LC/MS Modernization Tailwind!

Agilent Technologies, Inc. recently reported its fourth-quarter results for fiscal year 2025, showcasing robust performance across numerous...

Baptista Research

Primer: Agilent Technologies (A UN) - Sep 2025

Agilent is a well-positioned leader in the life sciences, diagnostics, and applied chemical markets, benefiting from a strong brand, diverse...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)